Diabetes is the leading cause of kidney failure. Additionally, elevated albuminuria predicts increased cardiovascular and renal risk. This publication summarises a post hoc analysis of the EMPA-REG OUTCOME trial examining the cardiovascular and kidney effects of empagliflozin in patients with different clinical phenotypes of diabetic kidney disease (DKD) as approximately one-third of patients had DKD at study entry. This review is sponsored by Boehringer Ingelheim and Eli Lilly. A free full-text PDF of the paper Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2020;22(12):2335-2347 is available here.
Please login below to download this issue (PDF)